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Hepatocytes are often regarded as “victims” and “bystanders” in liver fibrogenesis, but the role of  
hepatocytes in liver fibrosis is under-examined. Hepatocytes in normal and cirrhotic livers express 
the pro-angiogenic vascular endothelial growth factor A (VEGF-A) and the anti-angiogenic factor 
thrombospondin-1 (THBS-1) that might be involved in liver fibrogenesis. In order to unravel the 
role of  hepatocytes in liver fibrosis, we aimed to interfere with the angiogenic balance regulated by 
hepatocytes through delivering interferon alpha (IFNα) to the hepatocytes. In vitro using HepG2 
cells, we have previously shown that our construct, galactose-PEG-IFNα (GPI), was recognized 
by the asialoglycoprotein receptor (ASGPR) and has similar antiangiogenic effects as native IFNα. 
In the present study, we aimed to deliver GPI to the hepatocytes in vivo and to test its effect on 
angiogenesis in a fibrosis model of  CCl4-exposed mice with native IFNα used as positive control. 
Moreover, we aimed to get more insight in the role of  angiogenesis in fibrosis. The localization of  
the GPI in the liver was detected by immunohistochemical staining with an IFNα recognizing 
antibody. The results showed that GPI was not only found in hepatocytes, but also in other cell 
types (endothelial cells and (myo)fibroblasts) in the liver and no difference was observed between 
the distribution of  GPI and native IFNα. This suggests the presence of  the IFNα receptor 
(IFNAR) on other liver cells besides hepatocytes in the mouse. In the current study, both IFNα 
and GPI decreased the CD31 and VEGF receptor 2 (VEGFR2) expressions, suggesting inhibition 
of  angiogenesis by the lower dose, but not by the higher dose. In addition, an increased VEGF-A 
expression was found in parallel with this angiogenesis inhibition possibly indicating a feedback 
mechanism. The angiogenesis inhibition did not affect the liver fibrogenesis in this model, as 
expression of  collagen remained unaltered. 
In conclusion, in mice with liver fibrosis, IFNα treatment inhibited angiogenesis without 
affecting fibrosis. However, since we did not observe a difference in the cellular distribution of 
GPI and IFNα in the fibrotic liver, we cannot conclude on the role of hepatocytes in this 
angiogenesis inhibition. In this study, we also did not observe an effect of IFNα on fibrogenesis, 
despite a decrease in angiogenesis, suggesting that angiogenesis has no direct role in fibrogenesis 
but may occur as the consequence of increased profibrotic factors that also have an angiogenic 
effect.  








Hepatocytes comprise ~85% of the liver mass and have an important role in most of the functions 
of the liver, such as protein synthesis, glucose metabolism, fat digestion, drug metabolism and bile 
production 1,2. Hepatocytes are also prone to several injuries, including toxic, metabolic, and viral 
insults 3,4. Persistent injury can result in chronic inflammation and wound healing response and can 
lead to liver fibrogenesis 3,5. Hepatocytes are often regarded as “victims” and “bystanders” in liver 
fibrogenesis 1, however, it cannot be excluded that they also play a role in fibrogenesis. Recently, 
hepatocytes have been proposed to contribute to liver fibrosis through a process of  epithelial to 
mesenchymal transition, but this issue remains controversial 5-7.  
One of the characteristics in liver fibrosis is the existence of abnormal angioarchitecture due to 
the formation of new blood vessels, known as angiogenesis 8-10. Angiogenesis is tightly controlled 
by the balance of angiogenic activators and angiogenic inhibitors 11. Angiogenesis factors in the 
liver are produced by different cell types, one cell type can produce more than one angiogenic 
factor and each angiogenic factor can be produced by more than one cell type 8. Hepatocytes in 
normal and cirrhotic livers express several important pro- and anti-angiogenic factors, i.e. vascular 
endothelial growth factor A (VEGF-A) and thrombospondin 1 (THBS-1) 9,12,13. Therefore, we 
hypothesized that hepatocytes play role in liver fibrogenesis through angiogenesis.  
We aimed to unravel the role of hepatocytes in liver fibrogenesis by interfering with the balance 
of pro- and anti-angiogenic factors produced by the hepatocytes, through delivery of an anti-
angiogenic compound specifically to the hepatocytes. In this study, interferon alpha (IFNα) was 
used to inhibit angiogenesis because it has been shown in previous studies that IFNα can inhibit 
endothelial cell migration and proliferation and decrease the secretion of the pro-angiogenic factor 
VEGF in many human cancer cells 14-16. IFNα has been used for many years as a therapeutic 
cytokine in Hepatitis C treatment, hemangioma and cancer therapy 17,18. However, IFNα therapy is 
associated with a lack of therapeutic specificity due to the presence of interferon alpha receptors 
(IFNAR) in most of the tissues in the body 19. In the liver, IFNAR is expressed by hepatocytes 20 
and there is no specific report yet on the expression of IFNAR by other cell types in the liver. 
In chapter 2, we designed an IFNα construct with galactose-polyethylene glycol in order to 
specifically deliver it to the asialoglycoprotein receptor (ASGPR), which is expressed abundantly 
on hepatocytes and recognizes and internalizes galactosylated proteins 21,22. We designed this 
construct by coupling galactose-polyethylene glycol (gal-PEG) moieties to IFNα to enhance uptake 
in the hepatocytes. In the in vitro study, this modification of IFNα did not affect its biological 
activity and this construct had similar anti-angiogenic properties as native IFNα. In the current 
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study, we administered this construct, gal-PEG-IFNα (GPI), to mice with CCl4-induced liver 
fibrosis to evaluate its distribution in the liver in vivo and its effect on angiogenesis and fibrosis.  
 
2. MATERIALS AND METHODS 
2.1 Synthesis of gal-PEG-IFNα (GPI) 
IFNα (Jena Biosciences, Jena, Germany) was coupled to galactose-polyethyelene glycol-
succinimidyl carboxymethyl (galactose-PEG-SCM) ester (5 kDa, Jenkem Technology, Beijing, 
China) according to the procedure described in chapter 2.  
 
2.2 CCl4-exposed liver fibrosis mouse model  
Liver fibrosis was induced in six different groups of Balb/c mice (20-22g; Harlan). One group 
consisted of healthy mice (n=6) and the other five groups were exposed to CCl4 twice weekly by 
intra-peritoneal injections with increasing doses (week 1: 0.5 mL/kg; week 2: 0.8 mL/kg and week 
3-4: 1 mL/kg of a solution of 0.25 mL CCl4/mL olive oil, resulting in doses of 0.125, 0.2 and 0.25 
mL/kg respectively) for 4 weeks. In week 3 and 4, mice were treated intravenously with 100 µL 
phosphate-buffered saline (PBS) (n=5), IFNα 400 ng/mL/day (n=4), IFNα 2000 ng/mL/day 
(n=6), GPI 400 ng/day (n=5), and GPI 2000 ng/day (n=6) three times per week. The dose of GPI 
refers to the amount of IFNα in the construct. All groups were sacrificed at the end of week 4, 
blood and livers were collected for further analysis. To investigate the cellular distribution of IFNα 
and GPI in the liver, a single dose (100 µL) of 4000 ng/mL was injected intravenously 20 min 
before sacrifice. The experimental protocols were approved by the Animal Ethical Committee of 
the University of Groningen.   
 
2.3 Immunohistochemical staining 
To determine the distribution of IFNα and GPI and the protein expression of CD31 and collagen 
I, immunohistochemical staining was performed on cryostat liver sections (4 µm). Sections were 
fixed with acetone, rehydrated with PBS and incubated with the primary antibody in appropriate 
dilution, i.e rabbit polyclonal IFNα antibody (1:600, Thermo Scientific, Rockford, USA), rat 
monoclonal CD31 antibody (1:200, BD Pharmingen, San Jose, USA) or rabbit polyclonal collagen 
I antibody (1:50, Rockland, USA) for 1 h at room temperature. The sections were washed with 
PBS three times and further incubated with a horseradish peroxidase (HRP)-conjugated secondary 
antibody (1:100, DAKO, Belgium), followed by HRP-conjugated tertiary antibody (1:100, DAKO, 
Belgium), each for 30min. Peroxidase activity was developed with ImmPACT™ NovaRED™ 
(Vector Laboratories, Burlingame, USA) for IFNα staining and 3-amino-9-ethyl carbazole (Sigma, 







USA) for CD31 and collagen I staining. Subsequently, the nuclei were counterstained with 
haematoxylin (Fluka Chemie, Buchs, Switzerland). Staining quantification was performed on 
sections before counterstaining by using Aperio Imagescope (Positive Pixel Count Algorithm v9) 
and presented value is the ratio between the total area of CD31 or collagen I positive pixels (red) 
to the total area of pixels in percentage. 
Double staining was performed with red staining using NovaRed for IFNα staining to locate 
the injected compounds and blue staining using BCIP/NBT (Vector Laboratories, Burlingame, 
USA) for CD31 and goat polyclonal desmin antibody (1:100, Santa Cruz Buiotechnology, USA) to 
identify (myo)fibroblasts. 
 
2.4 Real-time quantitative RT-PCR  
The mRNA expression of angiogenesis and fibrosis markers in the mice liver was analyzed using 
real-time RT-PCR. Liver samples were snapped frozen and total RNA was isolated using the 
Maxwell® 16 LEV SimplyRNA Tissue Kit (Promega, Leiden, The Netherlands). The amount of 
isolated RNA was measured with an ND-1000 spectrophotometer (Fisher Scientific, Landsmeer, 
the Netherlands). Reverse transcription of RNA to cDNA was performed using Reverse 
Transcription System (Promega, Leiden, The Netherlands) in the Eppendorf master cycler gradient 
at 20 °C for 10 min, 42 °C for 30 min, 20 °C for 12 min, 99 °C for 5 min and 20 °C for 5 min. The 
mRNA level of each marker was measured using the SYBR Green Mastermix (GC Biotech, Alphen 
aan de Rijn, The Netherlands) and the following primers (50 µM): 
 
Table 1. List of primers used in this study 
Gene Forward Reverse 
Procollagen 1α1 TGACTGGAAGAGCGGAGAGT ATCCATCGGTCATGCTCTCT 
CD31 TCCCTGGGAGGTCGTCCAT GAACAAGGCAGCGGGGTTTA 
VEGF-A GTTCCCGAAACCCTGAGGAG CTGTGCAGGCTGCTGTAACG 
VEGFR2/KDR CAGGACTGAAAGCCCAGACTGT TCAGGCACAGACTCCTTCTCC 
b-actin ATCGTGCGTGACATCAAAGA ATGCCACAGGATTCCATACC 
 
The PCR reaction was performed using a 7900HT Real Time PCR (Applied Biosystems) with 
1 cycle of 10 min at 95 °C and 40 cycles of 15 secs at 95 °C and 25 secs at 60 °C with a dissociation 
stage at the end (95 °, 15 secs; 60 °C, 15 secs; 95 °C, 15 secs). Ct values were corrected for the Ct 









Liver homogenates were prepared in cold RIPA buffer (10 mL of RIPA buffer containing 50 mM 
Tris/HCl pH 7.5,150 mM NaCl, 0.1% Igepal in 0.5% sodiumdeoxycholaat, 0.1% sodium dodecyl 
sulphate (SDS), and 1 tablet of protease inhibitor) and sonicated for 90 secs. The lysates were 
centrifuged at 12,000 rpm for 1 h at 4 °C. The supernatants were stored at -80 °C until use. Protein 
expression of VEGF-A in the liver was determined by using the Murine VEGF Mini ABTS ELISA 
Development Kit (Peprotech, London, UK) with a small modification. Instead of using 2,2'-
Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS) substrate provided by 
the kit, 3,3’,5,5’- Tetramethylbenzidine (TMB) substrate (R&D Systems, Minneapolis, USA) was 
used. Color development was monitored with an ELISA plate reader at 450 nm wavelength and 
correction set at 550 nm. The calculated concentrations of VEGF-A in the liver homogenates were 
normalized with the total protein content of the liver homogenate, which was measured using 
Lowry (BioRad, Veenendaal, The Netherlands). 
 
2.6 Western Blot 
Liver homogenates were prepared as described for the ELISA. Homogenates containing 500 µg 
of protein were mixed with an equal amount of loading buffer (62.5 mM Tris/HCl pH 6.8, 10% 
glycerol, 2 % SDS, 1.55% dithiothreitol and 0.0125% bromophenol blue) and boiled at 95 °C for 
5 min. From each sample, 100 µg of protein was applied on SDS-polyacrylamide gel (7.5%). The 
gel was run by applying 150 V and subsequently transferred to polyviniylidene fluoride (PVDF) 
membranes. The membranes were blocked for 1h in tris-buffered saline with 0.1 % Tween 20 
(TBST) containing 5% non-fat dried milk (BioRad, Veenendaal, The Netherlands) and were 
incubated with mouse monoclonal THBS-1 antibody (1:500, Thermo Fisher Scientific, Rockford, 
USA) or rabbit monoclonal VEGFR2 antibody (1:1000, Cell Signaling Technology, Danvers, USA) 
or mouse monoclonal b-actin antibody (1:10000, Sigma, Saint Louis, USA) overnight at 4 °C. The 
membranes were further washed with TBST and incubated for 1 h at room temperature with HRP-
conjugated secondary antibody (1:2000, DAKO, Belgium). The membranes were washed with 
TBST for 30 min and with tris-buffered saline (TBS) for another 30 min. The protein bands were 
visualized using VISIGLO™ HRP Chemiluminescent Substrate Kit (Amresco, Solon, USA). 
 
2.7 Statistics 
The results were analyzed with One Way ANOVA followed with Dunnett’s Multiple Comparison 
using GraphPad Prism 7. Data are presented as mean ± standard error mean (SEM). A p-value < 
0.05 was considered significant. 








CCl4 exposure for 4 weeks reduced the bodyweight of the mice and treatment with either IFNα or 
GPI did not alter this reduction (Fig. 1A). White blood cell counts were highly increased by CCl4- 
treatment and a significant reduction was observed in mice treated with the lower dose of GPI 
compared to untreated fibrotic mice, but not with the high dose of GPI and both doses of native 
IFNα (Fig. 1B). The level of aspartate aminotransferase (AST) and alanine transaminase (ALT) in 
the blood were used as an indicator of liver injury, and were both increased in response to CCl4. 
Mice treated with the lower dose of IFNα showed a higher AST level compared to untreated 
fibrotic mice (Fig. 1C). This effect, however, was not observed at the higher dose and no 
difference was observed in the ALT level in the mice treated with either IFNα or GPI (Fig. 1D). 
 
Fig. 1 Effects of IFNα and GPI on body weight and white blood cell count in control and CCl4-
exposed mice. Fibrosis induction with CCl4 for 4 weeks reduced mice body weight (A) and 
increased white blood cell (WBC) count (B). Neither IFNα nor GPI altered the body weight 
reduction, but treatment with 40 ng of GPI significantly decreased the WBC in CCl4-exposed mice. 
(C) Significant increase in liver enzyme aspartate aminotransferases (AST) was observed in mice 
treated with 40 ng of IFNα but no effect was observed on ALT level (D).   
*p<0.05 compared to PBS-treated CCl4 mice. Data are presented as means (±SEM). n=4-6  
 
Immunohistochemical staining of IFNα in fibrotic livers of mice treated with IFNα or GPI 
showed that there was no difference in the distribution of native IFNα and GPI (Fig. 2A and 2B 
respectively). The staining showed that the location of both compounds was not specific for one 
cell type, but IFNα staining was found in the endothelial cells of the portal veins, arteries and 
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central veins, and was most prominent in the fibrotic septa but absent in the bile ducts (Fig. 2A, 
B). The staining was not found in the livers of animals that did not receive IFNα or GPI (data not 
shown). Moreover, staining was also observed in hepatocytes as cytoplasmatic staining and in some 
areas, the basolateral membrane was positive (Fig. 2C). Double staining with CD31 as endothelial 
cell marker and with desmin as (myo)fibroblasts marker confirmed the co-localization of both 
compounds in the CD31 positive endothelial cells (Fig. 2D) and desmin positive (myo)fibroblasts 
(Fig. 2E).  
 
 
Fig. 2 Distribution of IFNα (A) and GPI (B) in the CCl4-exposed mice liver. The positive staining 
(red) shows the location of respectively IFNα and GPI. There was no difference in the distribution 
of both compounds, the staining was found in the endothelial cells of the portal vein (pv), artery 
(a), and central vein (cv), staining was prominent in the fibrotic septa (f) and absent in the bile 
ducts. The staining of GPI in the cytoplasm and basolateral membrane of the hepatocytes is 
indicated with the black arrow in (C). The red arrow in (D) shows the co-localization of the GPI 
(red) in CD31 positive cells (blue). While the blue arrow in (E) shows the co-localization of the 
GPI (red) in desmin positive cells (blue). Pictures in (C, D, E) are similar for IFNα (not shown) 
Scale bars = 300 µm (top figures) and 50 µm (bottom figures). 
 
CD31, the endothelial cell marker, was used as a surrogate marker for angiogenesis. In healthy 
mice, the CD31 staining was located on larger veins and arteries with faint staining along the 
sinusoids (Fig. 3A1). In CCl4-exposed mice, the CD31 protein expression was strongly increased 
and this CD31 staining was prominent in the fibrotic septa in addition to the vascular and 







sinusoidal endothelial localization indicating angiogenesis (Fig. 3A2). VE-cadherin staining 
showed similar pattern to the CD31 staining in the liver of healthy and fibrotic mice (data not 
shown). Treatment of fibrotic mice with the lower dose of IFNα and GPI reduced the CD31 
protein expression (Fig. 3A3, 3A5, 3B), confirming the anti-angiogenic effect of IFNα but the 
higher dose of both compounds did not affect the CD31 protein expression significantly (Fig. 
3A4, 3A6, 3B). Remarkably, the CD31 mRNA expression was similar in control and fibrotic livers 
and no effect was observed in mice treated with either IFNα or GPI (Fig. 3C). 
 
 
Fig. 3 Effect of IFNα and GPI on the level of the endothelial cell marker (CD31) in CCl4-exposed 
mice. (A) In healthy controls, strong CD31 staining was observed in veins and arteries and faint 
staining was seen in the sinusoids (A1). A strong CD31 staining was visible in fibrotic septa (A2) 
in PBS-treated CCl4 mice in addition to the vascular and sinusoidal endothelial staining, which was 
suppressed by the low dose of both IFNα (A3) and GPI (A5) but not by the high dose (A4, A6). 
The results of the quantification CD31 protein expression are given in (B) as percentage of stained 
area.  Fibrosis induction with CCl4 did not alter the mRNA expression of CD31 (C) (mRNA levels 
of CD31 in all groups were normalized with b-actin as housekeeping gene). 
*p<0.05 compared to PBS-treated CCl4 mice. Data are presented as means (±SEM). n= 4-6 
Scale bars = 200 µm 
 
Our previous in vitro study showed the effects of IFNα and GPI on VEGF-A and THBS-1 in 
HepG2 cells. Both compounds showed anti-angiogenic effects by decreasing the protein 
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expression of the pro-angiogenic factor VEGF-A and increasing the expression of the anti-
angiogenic factor THBS-1. In contrast, in the fibrotic liver in vivo both compounds increased the 
pro-angiogenic VEGF-A protein expression without any effect on the mRNA expression (Fig. 
4A, 4B). In addition, the untreated CCl4-exposed mice showed a lower VEGF-A mRNA and 
protein expression (Fig. 4A, 4B) compared to the healthy controls. Moreover, the THBS-1 
expression was reduced in CCl4 treated animals compared to healthy animals, but was not affected 
by either IFNα or GPI at mRNA (data not shown) and protein level (Fig. 4C). 
 
 
Fig. 4 Effect of IFNα and GPI on the expression of angiogenic factors in CCl4-exposed mice. 
Fibrosis induction with CCl4 decreased the mRNA (A) and protein (B) expression levels of the 
pro-angiogenic factor VEGF-A in the liver. VEGF-A protein expression was determined with 
ELISA and expressed relative to the total protein in the liver. Treatment with 40 ng IFNα and GPI 
increased VEGF-A protein expression. (C) Western blot analysis of THBS-1 and VEGFR2; b-
actin was used as loading control. Along with a decreased VEGF-A expression in CCl4-exposed 
mice, the protein (D) and mRNA (E) expressions of its receptor (VEGFR2) were also decreased. 
Treatment with IFNα and GPI (40 ng) further reduced the VEGFR2 protein expression, but its 
mRNA expression remained unchanged.  
*p<0.05 compared to PBS-treated CCl4 mice. Data are presented as means (±SEM). n=4-6 
 
VEGF-A binds to VEGF receptor 1 and 2 (VEGFR1 and VEGFR2) but exerts its angiogenic 
effect only through VEGFR2 8,23,24. In the current study, fibrotic mice treated with the lower dose 







of IFNα and GPI had lower protein expression of VEGFR2 compared to untreated fibrotic mice 
(Fig. 4C, D). This result is consistent with the effect of both IFNα and GPI at lower dose on 
CD31 and VEGF-A protein expressions. However, we did not observe any effect of the treatment 
on VEGFR2 expression at mRNA level (Fig. 4E).  
 
 
Fig. 5 Effects of IFNα and GPI on the levels of fibrosis in CCl4-exposed mice. Both IFNα and 
GPI did not affect the mRNA levels of procollagen 1α1 (C) and the protein levels of collagen I 
(D) in CCl4-exposed mice. (E) Photomicrographs of representative collagen I staining (red) in 
mice livers.  
*p<0.05 compared to PBS-treated CCl4 mice. Data are presented as means (±SEM). n=4-6 
Scale bars = 300 µm 
 
Lastly, we investigated the effect of IFNα and GPI on liver fibrogenesis. Both IFNα and GPI 
showed no effect on the mRNA expression of procollagen 1α1 and on the collagen I protein 
expression compared to untreated fibrotic mice (Fig. 5C, D, E). Similar results were obtained for 








In this study, we aimed to target IFNα to the hepatocytes of mice with CCl4-induced liver fibrosis 
by coupling it to galactose-PEG. However, the in vivo results show that there was no difference in 
cellular distribution of IFNα and GPI in the liver. Both compounds showed binding to endothelial 
cells, (myo)fibroblasts and hepatocytes and no difference in the relative distribution among these 
cell types was observed between IFNα and GPI. The galactose ligand coupled to the IFNα was 
hypothesized to drive the GPI to the ASGPR expressed by hepatocytes. Both IFNα and GPI 
induced STAT1 phosphorylation in HepG2 cells, which in case of GPI could be inhibited by 
lactosylated HSA, suggesting the involvement of the ASGPR to the effect of GPI (chapter 2). In 
the current in vivo study, no such targeting to the ASGPR on hepatocytes could be observed from 
the immunohistochemical data.  
The lack of targeting of GPI to the hepatocytes in vivo might be due to the fact that binding of 
both IFNα and GPI to the IFNAR is much higher on the endothelial cells, (myo)fibroblasts and 
hepatocytes, than binding to the ASGPR. As a consequence, the binding to the ASGPR on the 
hepatocytes is negligible compared to the binding to the IFNAR.  IFNAR is a common receptor 
for type I interferons including IFNα and consists of two subunits, a low- (IFNAR1) and a high-
affinity (IFNAR2) receptor component 19,25. IFNAR1 and IFNAR2 form a heteromeric complex 
upon binding and activation by type I interferons 19,25. The distribution of IFNAR on hepatocytes 
has been previously reported 19,20. Although there has not been any study yet showing the 
distribution of IFNAR expression in the liver other than hepatocytes, the reported IFNAR 
expression in human umbilical vein endothelial cells 26 and cardiac fibroblasts 27 suggests that 
IFNAR might be also expressed by endothelial cells and fibroblasts in the liver. Indeed, our 
histochemical results for the first time indicate the binding of IFNα in vascular and sinusoidal 
endothelial cells, (myo)fibroblasts and hepatocytes of the fibrotic mouse liver, which is similar to 
that of GPI, suggesting the presence of IFNAR in these cells, thereby supporting our hypothesis 
on the lack of effect of targeting of IFNα.   
Another explanation is that GPI might bind to scavenger receptors expressed by endothelial 
cells 26,28, macrophages 28,29 and hepatic stellate cells 30. Binding of gal-PEG to IFNα increases its 
negative charge and it is known that negatively charged proteins are substrates for scavenger 
receptor-mediated internalization 28. This increased binding of GPI compared to IFNα to the 
scavenger receptor could have counteracted the binding to the ASGPR on the hepatocytes. 
However, we did not observe a difference in the binding of GPI and IFNα. Thus, we think that 
the scavenger receptor is less likely to influence the binding of GPI compared to the IFNAR. The 
third explanation is the internalization of GPI by ASGPR might degrade the compound, thereafter 







cannot be detected by immunohistochemical staining. Whether the compound was rapidly 
internalized and degraded in hepatocytes remains to be tested. The ASGPR is still present on 
hepatocytes in fibrotic mice (data not shown). 
In order to test whether coupling to gal-PEG would reduce the systemic immunosupressive 
effect of IFNα, WBC count was assessed as an inflammation marker. The increased WBC count 
in the mice exposed to CCl4 indicates the inflammation that accompanies fibrosis. A decrease of 
WBC count was found in fibrotic mice treated with the lower dose of GPI, which might indicate 
less inflammation, although intrahepatic TNFα level was not reduced (data not shown). 
Nevertheless, a decrease of WBC count might also indicate IFNα-mediated bone marrow 
suppression 31,32, due to the presence of IFNAR in the bone marrow 33. However, the effect on the 
WBC count was not observed in mice treated with native IFNα. This might be due to the higher 
systemic exposure to GPI compared to IFNα, as it is well known that pegylation can cause 
prolongation of the half-life in the blood circulation, as was shown by Bansal et al. for IFNγ coupled 
to 5kD PEG 34. Of note, their results also showed that PEG-IFNγ decreased the WBC count and 
there was no difference in WBC count when IFNγ was coupled to PEG of different size. The 
result in our study showed that the conjugation of galactose to PEG apparently does not reduce 
the systemic effect of IFNα. 
To investigate the effect of GPI on angiogenesis, we used CD31 as marker for endothelial cells. 
Angiogenesis emerges in parallel with liver fibrogenesis 8-10. Indeed, immunohistochemical staining 
showed an increased CD31 protein expression that was observed in the sinusoids in the fibrotic 
septa in fibrotic mice. Surprisingly, in this experiment we did not observe a difference in CD31 
mRNA expression between healthy mice and CCl4-exposed mice, indicating upregulation at the 
posttranslational level. Treatment with the lower dose of IFNα and GPI reduced the CD31 protein 
expression significantly, indicating indeed an anti-angiogenic effect. The effect, however, was not 
observed with the higher dose of both IFNα and GPI. Such a U-shaped dose-response was also 
found in our in vitro study on the effect of IFNα and GPI using HepG2 cells and HUVEC. A U-
shaped dose response was also observed for the anti-angiogenic effects of IFNα in human bladder 
cancer 35. In addition, several other molecules, used for therapeutic targeting of angiogenesis in 
cancer, have been shown to display hormesis with bell-shaped, U-shaped or J-shaped dose-
response curves 36.  
VEGF-A is also well known as marker of angiogenesis because an increase in VEGF-A 
expression is correlated with the progression of angiogenesis 24,37. However, we observed a different 
result in our study. Compared to healthy mice, the mice that were exposed with CCl4 had a 
decreased VEGF-A expression in parallel with the increased CD31 protein expression. This 
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decrease of VEGF-A expression in fibrotic mice was also observed by Kantari-Mimoun et al., in 
mice that were exposed with CCl4 for 12 weeks. When the mice were left untreated for 4 weeks 
(recovery period), the VEGF-A expression increased again in parallel with a decrease of fibrosis 
markers 38,39.  
The increase of VEGF-A expression after treatment of fibrotic mice with free IFNα or GPI is 
inconsistent with the result from the findings with HepG2 cells in chapter 2, which showed a 
decrease of VEGF-A expression upon exposure to IFNα and GPI. This discrepancy between the 
results in HepG2 cells and in the fibrotic mouse livers could indicate a species difference. However, 
it is always difficult to extrapolate in vitro data in cell lines to the in vivo situation during disease 
progression. Moreover, we have strong indications that the effect of IFNα in the liver is an overall 
result of the effect in several different cell types in addition to that in hepatocytes. An anti-
angiogenic effect that is accompanied by an increased VEGF-A expression was also observed in a 
study using cilengitide, an inhibitor of integrin αvβ3 and αvβ5, to assess its anti-angiogenic effect 
in liver fibrosis. Cilengitide inhibited angiogenesis in bile duct ligation and thioacetamide-induced 
liver fibrosis in the rat but aggravated liver fibrogenesis 40. The increased VEGF-A expression along 
with decreased CD31 expression could indicate a feedback mechanism due to hypoxia. The lack 
of supplying blood vessels because of the angiogenesis inhibition can compromise oxygen delivery 
to the liver parenchyma 40. As a consequence, the expression of hypoxia-inducible proteins is 
increased, including the expression of VEGF-A 40. Interestingly, a decreased VEGFR2 expression 
was also observed after IFNα treatment. This decreased VEGFR2 expression might be the reason 
why the increased VEGF-A expression did not result in increased angiogenesis. In addition to 
VEGF-A, we also investigated the effect on THBS-1 to explain the anti-angiogenic effect observed 
in this study, but we did not find any difference in the expression of THBS-1 at mRNA and protein 
level. A possible explanation of the effect of IFNα and GPI on angiogenesis in our study is a direct 
effect on endothelial cells, assuming that IFNAR is present in these cells, which is supported by 
the immunohistochemical localization 19,25.  
Lastly, one of the aims of this study was to evaluate the role of angiogenesis in liver fibrosis. In 
this study, we did not observe any effect on the fibrosis markers upon angiogenesis inhibition. We 
are not the first to observe this. In the study conducted by Kantari-Mimoun et al., genetic ablation 
of VEGF in scar-infiltrating myeloid cells inhibited angiogenesis in 12-week CCl4-exposed mice 
but did not affect liver fibrogenesis 38. Although our immunohistochemical studies suggest that the 
IFNAR is expressed by the HSC, it seemed that treatment with IFNα or GPI did not influence the 
liver fibrogenesis. 







In conclusion, we have successfully inhibited angiogenesis in CCl4-exposed mice with IFNα and 
GPI. However, since we did not observe a difference in the cellular distribution of both 
compounds in the fibrotic liver, we cannot conclude on the role of hepatocytes in this angiogenesis 
inhibition. In this study, we also did not observe an effect of IFNα on fibrogenesis, despite a 
decrease in angiogenesis, suggesting that angiogenesis has no direct role in fibrogenesis but may 
occur as the consequence of increased profibrotic factors that also have an angiogenic effect.  
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